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Abstract: The increasing rates of resistance among bacteria and to a lesser extent fungi have resulted in an urgent need to 
find new molecules that hold therapeutic promise against multidrug-resistant strains. Antimicrobial peptides have proven 
very effective against a variety of multidrug-resistant bacteria. Additionally, the low levels of resistance reported towards 
these molecules are an attractive feature for antimicrobial drug development. Here we summarise information on diverse 
peptide libraries used to discover or to optimize antimicrobial peptides. Chemical synthesized peptide libraries, for 
example split and mix method, tea bag method, multi-pin method and cellulose spot method are discussed. In addition 
biological peptide library screening methods are summarized, like phage display, bacterial display, mRNA-display and 
ribosomal display. A few examples are given for small peptide libraries, which almost exclusively follow a rational design 
of peptides of interest rather than a combinatorial approach.  
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1. Antimicrobial resistance  
The use of antibiotics since the early 20th century has helped 
reduce death and illness associated with infectious diseases 
[1]. Antibiotics are not only used to treat existing bacterial 
infections but are also commonly used as prophylaxes for 
many different medical procedures, for example operations 
and transplants. Antibiotics are therefore a critical pillar in 
medicine and arguably one of the greatest triumphs in the 
history of modern medicine. Antibiotics were first discovered 
in the 1930s and made publically available soon after, 
however within a few years resistance had already been 
reported among the sulphonamide class, the first antibiotics to 
be discovered [2]. Over the years there has been a huge surge 
in antibiotic resistance due to their wide availability, 
indiscriminate use (sore throat, neck pains, common colds and 
viral infections) and availability in unregulated markets[3]. 
Patients being incompliant by not finishing the course of 
medication or stockpiling for future use, and overuse in 
animal husbandry has further exasperated the problem[4]–[6]. 
Recently the emergence of multidrug-resistance (MDR) and 
extensive drug-resistant (XDR) organisms has been a more 
alarming issue.  MDR usually occurs in a healthcare 
environment and mostly in situations where the patient is in a 
critical or vulnerable condition, such as those in intensive care 
and neonatal units[3],[7]. Bacteria which have developed 
MDR phenotypes include Methicillin resistant 
Staphylococcus aureus (MRSA), Vancomycin Resistant 
Enterococci (VRE) and MDR Mycobacteria tuberculosis. 
There have been many reported cases of extensively drug 
resistant M. tuberculosis (XDR-TB) [8], and even reports of 
total drug resistance (TDR-TB)[9]. MDR is also seen amongst 
a group of Gram positive and Gram negative bacteria, which 
have been dubbed the “ESKAPE” group (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter spp.) [10]. These pathogens are of emerging 
clinical importance due to their prevalence in nosocomial 
(especially in intensive care units) and community settings.  
Since the golden age of antibiotic discovery in the mid-1900s 
the development of new antibiotics decreased significantly 
(Figure 1) thus creating an urgent need for the development of 
novel antimicrobials that can kill multidrug- resistant bacteria 
[11]. 
Figure 1. Decrease in antibiotic approval by the FDA has 
coincided with an increase in the resistance of pathogens to 
currently available drugs, creating an urgent need for novel 
antimicrobial development. Adapted from [10],[12],[13] 
 
2. Antimicrobial peptides 
Antimicrobial peptides have recently been receiving much 
attention due to several attributes that make them attractive 
candidates to treat multidrug-resistant infections. Perhaps 
most importantly is the fact that they have shown activity 
towards a wide spectrum of pathogens including gram 
positive and gram negative bacteria [14], fungi[15] 
viruses[16], protozoa [17] and organisms with multidrug-
resistant phenotypes [18]–[20]. This is coupled with the fact 
that antimicrobial peptides (AMP’s) have shown a lower 
propensity for inducing bacterial resistance compared 
to  other antibiotics [21]  and they also have the ability to 
target metabolically inert cells e.g. those in latent infections 
[22] and biofilms [11].  
Whilst the design and synthesis of novel antimicrobial 
peptides is becoming increasingly common in laboratories 
worldwide, for a long time nature has utilised antimicrobial 
peptides in all kingdoms of life to defend against pathogenic 
invasion, or in the case of microorganisms to ward off 
competitors for nutrients. Some examples of peptides found 
in nature can be seen in Table 1. In many cases utilisation of 
these peptides by the immune system is not limited to their 
direct killing of pathogens as they can also lead to an induction 
of chemokine release[23], modulation of inflammatory 
response[24] and promotion of wound healing [25].  
Antimicrobial peptides (AMP’s) are not restricted to one 
mode of action, in fact several cellular target sites have been 
reported[15],[26]–[28]. The most commonly described target 
for antimicrobial peptides is the microbial cell membrane. 
Due to the fact that the prokaryotic membrane generally 
contains a higher proportion of negatively charged 
phospholipids then mammalian cell membranes[29], and that 
most AMP’s have a net positive charge [30] peptides are able 
to selectively interact with microbial cells. However, this 
selectivity is not always very pronounced and one of the 
challenges to identifying therapeutically viable antimicrobial 
peptides is the identification of those with an optimised 
therapeutic window.  
Numerous different peptides have been identified that can 
cause extensive membrane disruption, depolarisation and cell 
death [31]–[33]. For these membrane active peptides at least 
three different mechanisms have been identified. A barrel 
stave model of membrane pore formation whereby peptides 
insert into the lipid bilayer in a perpendicular manner. A 
toroidal model where peptides are inserted into the membrane 
perpendicularly but the resulting pore is lined by intercalated 
peptide and lipid head groups. The carpet mechanism where 
peptides remain parallel with the membrane but have a 
detergent like effect leading to significant membrane 
disruption [34]. Although the disruption of microbial 
membranes is the most studied mechanism by which peptides 
cause cell death it is by no means the only mechanism. The 
vast heterogeneity of antimicrobial peptides is illustrated by 
the fact that inhibition of cell walls synthesis, inhibition of 
DNA, RNA and protein synthesis, inhibition of septum 
formation, binding and sequestering of lipid II, and inhibition 
of ATP dependent enzymes have all been proposed as 
mechanisms which may individually or simultaneously  lead 
to cell death[15],[27],[35]–[39].  
There are some common features among AMP’s, many are 
amphipathic, contain 12-50 amino acids and possess a net 
positive charge. There are however exceptions to the rule as 
antimicrobial activity has been found in peptides ranging from 
<10 to >100 amino acids in length [40] and in anionic 
peptides[41]. The number of possible amino acid 
combinations that can be achieved within this range is vast, 
however this number is further amplified when considering 
the wide spread use of non-natural amino acids and chemical 
modifications.  This diversity is well illustrated by databases 
of antimicrobial peptides such as the APD2 database which 
currently lists 2523 unique  AMP sequences found in nature 
[40]. A range of different structures exists among these 
antimicrobial peptides including α-helices e.g. magainin[42], 
β-sheets e.g. defensins[43] and random coils e.g. histatins[44] 
(Figure 2). However, many antimicrobial peptides are 
believed to undergo structural alteration during transition 
from aqueous environments to amphiphilic environments 
such as those within cell membrane [44],[45]. 
 
 
Figure 2. Structures of different antimicrobial peptides. A. α-
helix, Magainin in solution NMR; (PDB: 2LSA) B. β-sheets, 
HNP-3 Defensin via X-Ray diffraction; (PDB: 1DFN) C. 
Random coil, Indolicidin in solution NMR (PDB: 1QXQ)  
In this review we will focus on novel antimicrobial peptide 
discovery or optimisation of existing peptides through the use 
of both combinatorial libraries prepared through chemical 
synthesis and biological libraries. Additionally due to the fact 
that a lot of the literature from the AMP field describes the 
synthesis of libraries with a small number of representatives 
obtained by solid phase peptide synthesis we will also include 
a third class – small peptide libraries. Some examples of 
AMP’s found using various peptide libraries have been given 
in Table 2. 
3. Chemical synthesized Peptide Libraries  
3.1. “Split and Mix” Method 
The “Split and Mix” method is used for the preparation of 
“combichem” libraries of peptides and is based on the 
Merrifield method for solid phase peptide synthesis[46]. 
Initially Boc chemistry was used for the Nα  protection of the 
amino group of an amino acid. The method was designed by 
A. Furka and it was first published as a poster on the 14th 
International Congress of Biochemistry in Prague in 1988 
with the title “Cornucopia of peptides”. Following the 
introduction of the base-liable Fmoc group for Nα protection 
“split and mix” libraries were also prepared using Fmoc 
chemistry. This method does not differ much from the 
conventional Solid Phase Peptide Synthesis (SPPS), however 
it includes dividing the resin into equal portions, then coupling 
each of the portions with one amino acid at a time. This is then 
followed by mixing of the resin portions and again dividing it 
before the next coupling of the subsequent amino acid takes 
place [47],[48] (see Figure 3B). Distinctive features of this 
method are that it can result in obtaining all possible 
combinations between the individual building blocks 
(combinatorial principle) and also the compounds synthesized 
are believed to be in one to one molar ratio, which is important 
for subsequent screening methods. The “split and mix” is a 
parallel synthesis on solid support that can either result in a 
mixture of compounds if the resin beads are combined prior 
to cleavage or if the resin beads are separated, then individual 
compounds can be cleaved and tested (one bead one 
sequence). Both mixtures and individual sequences produced 
by combinatorial approaches need the use of deconvolution 
methods to decipher the component or components with the 
desired activity [47]  
In the search of AMPs with improved activities the 
“combichem” approach was first explored by the group of 
Blondelle et al. in 1994[49]. Their work  focused on the 
preparation of combinatorial libraries using tetrapeptides  N-
acetylated (Ac-UZZZ-NH2) and non-acetylated (UZZZ-NH2) 
template sequences, where the U position is a defined amino 
acid and the Z position can be taken by any L-, D-, or 
unnatural amino acid (in total 56 building blocks were used 
as  D- and L-Cys were omitted for the Z position). After 
obtaining the 58 different peptide mixtures, each of which 
containing 563 or 175,616 different peptides, they were 
screened for anti-staphylococcal activity and the non-
acetylated peptides showed better activity.  An iterative 
selection procedure was then performed aiming to identify the 
sequences with the highest antimicrobial activity[49]. The 
peptide mixture (αFmoc-ԑlys)ZZZ-NH2   showed the greatest 
activity against S. aureus with a MIC  ranging from 78 to 156 
µg/ml. Then based on these results a new mixture of peptides 
was synthesized using (αFmoc-ԑlys)ZZZ-NH2 as a template, 
where the second position of the library was now defined. 
After three iteration steps two peptides showed MIC values 
against S. aureus and S. sanguis ranging from 3 to 4µg/ml . 
Interestingly, the same peptides were weakly active against E. 
coli with MIC values ranging from 31-128 µg/ml. Two years 
later Blondelle et al. published another paper focusing this 
time on antifungal hexapeptide combinatorial libraries 
prepared using the 20 natural L-amino acids. Solution 
mixtures of peptides were obtained after using the “split and 
mix” technique and were then tested in microdilution assays 
in a 96 well plate format from which IC50 values against 
Candida albicans were determined. One of the mixtures (Ac-
OOXXXX-NH2   where O is a defined amino acid and X can 
be any of the 20-L amino acids) showed strong anti-Candida 
activity. An iterative approach was applied to the mixture and 
one amino acid at a time was defined, the process consisted of 
four steps and each step resulted in a twenty times lower 
number of components in the mixture. The last step identified 
peptide Ac-RRWCKR-NH2 as the most potent anti-Candida 
peptide. The MIC range of the peptide against C. albicans was 
determined to be between 67-130 µg/ml. Additionally some 
of the  peptides from the Ac-OOXXXX-NH2 library showed 
broad spectrum antimicrobial activity against both S. aureus 
and E. coli with no or low haemolytic activity[50].  
  
 
Name Origin Sequence Length Net Charge % 
hydrophobicity 
 Reported antimicrobial 
Activity 
Ref 
Temporin K European common frog, Rana 
temporaria 
LLPNLLKSLL 10 2 60% Gram + [51] 
Bactenecin Bovine neutrophils. Bos Taurus RLCRIVVIRVCR 12 4 66% Gram +/- [52] 
Halictine Bee venom,  Halictus sexcinctus GMWSKILGHLIR 12 3 50% Gram +/- antifungal  [53] 
Gramicidin B Bacteria, Bacillus brevis VGALAVVVWLFLWLW 15 0 93% Gram +/- [54] 
Tachyplesin III Horseshoe crab, Tachypleus 
gigas 
KWCFRVCYRGICYRKCR 17 7 47% Gram +/- [55] 
Duramycin Bacteria, 
Streptoverticillium 
griseoverticillatum 
CKQSCSFGPFTFVCDGNTK 19 1 36% Gram + [56] 
Hainanenin 1 Hainan cascade-frog, Amolops 
hainanensis 
FALGAVTKLLPSLLCMITRKC 21 3 61% Gram +/- antifungal  [57] 
Hominicin Bacteria 
Staphylococcus hominis 
ITPATPFTPAIITEITAAVIA 21 -1 57% Gram +/- [58] 
Human 
neutrophil 
peptide-1 
Humans, Homo sapiens ACYCRIPACIAGERRYGTCIYQGRLWAFCC 30 3 53% Gram +/- antiviral, antifungal, 
antiparasitic, anti-HIV 
[59] 
Pardaxin 1 Red Sea moses 
sole, Pardachirus pavoninus 
GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE 33 0 45% Gram +/- [60] 
Nisin A Bacteria, Lactococcus lactis ITSISLCTPGCKTGALMGCNMKTATCHCSIHV
SK 
34 3 44% Gram + [61] 
Human beta-
defensin 1 
Humans, Homo sapiens DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKA
KCCK 
36 4 36% Gram +/- antiviral,  [62] 
LL-37 Humans, Homo sapiens  LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR
TES 
37 6 35% Gram +/-antiviral, antifungal 
antiparasitic 
[63] 
Buforin I Toad, Bufo bufo gargarizans AGRGKQGGKVRAKAKTRSSRAGLQFPVGRV
HRLLRKGNY 
39 12 28% Gram -/+ antifungal, [64] 
Lucifensin Bottle fly, Lucilia sericata ATCDLLSGTGVKHSACAAHCLLRGNRGGYCN
GRAICVCRN 
40 4 45% Gram + [65] 
Table 1. Examples of antimicrobial peptides discovered in nature 
  
 
Shortly after their discovery combinatorial approaches started 
incorporating a focus on a rational design of molecules rather 
than using completely random strategies for library 
construction. One of the studies that illustrates the evolution 
in the combinatorial approach is described by Rausch et al, 
focusing on the rational design of beta-sheet pore forming 
peptides [66]. The peptides for the study were synthesized 
with the “split and mix” method and a 26 residue framework 
was used in the construction of the library. The rationale of 
the group was aimed towards discovering a new sequence 
motif in a peptide, which will promote self-assembly into 
membrane spanning beta-sheets. The 26 residue framework of 
a beta-sheet prototype structure was designed to resemble 
common features associated with pore-forming, naturally 
occurring peptides known to possess a beta-structural motif. 
These features included a short amphipathic dyad repeat 
followed by a region consisting of basic residues[48]. Dyad 
repeats are characteristic features of beta-barrel structures and 
are encoded in the amino acid sequences of the membrane 
interacting surface of the beta barrels. The dyad repeat pattern 
consists of alternating amino acid residues oriented either 
towards the lipid bilayer or towards the barrel 
interior[67].  The 26 residue prototype hairpin structure 
included two dyad repeat motifs separated by a four residue 
turn structure. Six positions were chosen to be the 
combinatorial sites in the 26 amino acid framework and three 
of them were juxtaposed in the dyad repeats of the hairpin 
structure. A hydrophobic variable region designated OH 
(G,A,V,I,L,F,Y) (where amino acids are described with their one 
letter code) was chosen to be the start of the putative hairpin 
structure in the beginning of both of the strands. The OH 
region of the strands was followed by a OG/S,T site  that would 
incorporate glycine and either serine or threonine  as these are 
the three most abundant amino acids on the inside of a 
membrane beta-barrel structure [68]. Just one position away 
from the OG/S,T site  the OP region was located and the full set 
of acidic, basic and polar amino acids was varied within this 
region. Rausch et al. demonstrated a combinatorial library 
construction using the one bead, one sequence approach of 
screening. The beads were separated into 96 well plates and 
the potency of membrane permeabilization of each one of the 
sequences after cleavage from the photoliable linker was 
assessed by using lipid bilayer vesicles. The vesicles 
incorporated lanthanide metal terbium (Tb3+), while 
dipicolinic acid (DPA) was added to each of the wells of the 
96 well plate. If the peptides were able to lyse the vesicles then 
a Tb3+ /DPA complex is formed.  Tb3+/DPA complex is able 
to luminesce and the results can be read visually. The high 
throughput assay identified 30 peptides with the strongest 
ability to permeabilize lipid bilayers and the sequences of the 
strongest acting peptides were defined by Edman degradation. 
In all of the strongest acting peptides a conserved sequence 
motif was found to be present.  
 In a different study it was shown that short peptides (9-15 
amino acids in length) obtained from “split and mix” 
combinatorial libraries were able to permeabilize artificial 
bilayers [69], however a shared sequence motif amongst them 
was not identified. On the other hand the most active peptides 
shared some common compositional features, secondary 
structure and core hydrophobicity. Based on these results the 
authors hypothesized that membrane permeabilization is 
dependent on the so called interfacial activity or the ability of 
the peptide to alter the packaging of lipids and their 
organisation in the membrane rather than formation of stable 
transmembrane pores. Interestingly Rausch et al. also initially 
thought the beta sheet peptides were able to form stable 
transmembrane pores[66], however  this was proven to be an 
incorrect hypothesis in their later work where they 
showed  beta-sheet peptides with the strongest potential to 
permeabilize vesicles are not  partitioning in a stable 
transmembrane conformation, but are rather thought to cause 
transient pores[70].  
In a recent study by Krauson et al[71] an iterative 
combinatorial library was synthesised based on the 26 residue 
consensus sequence of membrane permeable, beta sheet 
antimicrobial peptides found by Rausch et al[70]. Six 
positions in the 26 mer peptide were subject to substitution 
with different amino acids. The general structure of the 
peptide was: RRGxxLxLALAKDGWALMLxLxxGRR-NH2, 
where (x) denotes the variable positions. Again an artificial 
lipid vesicle assay was used for the screen of the new library 
but this time with increased stringency in the peptide to lipid 
ratio. In addition to that, the assay was able to identify 
peptides at equilibrium i.e. peptides able to maintain long term 
membrane disruption as opposed to causing transient 
interactions on the surface of the vesicles. The study identified 
much stronger acting peptides in a peptide to lipid ratio of 
1:1000 in comparison to 1:50 for the representatives of the 
first library, implying that the optimised peptides might have 
adopted a membrane spanning beta-sheet conformation. 
Interestingly the most potent candidates showed inconsistent 
results when tested against biological membranes, thus 
concluding that the vesicle-based screen can be used as a 
powerful tool in the first line of selection of potential 
candidates. However in order to optimise and improve the 
structures that hold promise a combination of methods that 
translate better in vivo should be applied. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation illustrating the three methods for parallel synthesis on resin for the preparation of 
combinatorial libraries. A. “Multi pin” method[72]: 96 polypropylene pins with poly acrylic acid pin heads mounted on a frame 
above a 96 well plate, where each well contains an activated amino acid solution (left panel).  In order for elongation of the 
peptide chain to take place the multi pin frame has to be dipped in the wells of the 96 well plate (right panel). B.”Split and mix” 
method[73]: the synthesis of a tripeptide with all the possible combinations obtained from coupling of the individual amino acids 
is illustrated (modified from[47]) . Initially the resin beads (illustrated as spheres) are separated into three reactors. Then a 
coupling step with three different amino acids takes place. After the coupling step the resin beads are combined into one reactor. 
This is then followed by a subsequent splitting of the resin into equal portions in three separate reactors, where a second coupling 
takes place. The resin beads with the prepared 
dipeptides are then again combined into one reactor. The procedure is repeated and finally tripeptides are obtained containing all 
possible combinations of the three amino acids. C. Tea-bag method[74]: polypropylene mesh bags are filled with resin beads and 
are placed into a beaker with an activated amino acid solution. Depending on the sequence to be synthesized the bags can be then 
dipped into different beakers each dedicated for the desired amino acid solution. 
 
 3.2. “Tea bag” method 
Another approach for “combichem” libraries preparation 
using standard SPPS synthesis is the “tea bag” method 
designed by R. A. Houghten in 1985[74] (see Figure 3C). 
The method uses labelled polypropylene mesh bags (15 mm 
x 20 mm) containing resin beads onto which the peptides are 
synthesised. The method includes all the steps of a standard 
solid phase peptide synthesis protocol. Similarly to the “split 
and mix” method it was initially designed to be used with 
Boc chemistry. Later on a protocol for peptide synthesis 
with “tea bags” using Fmoc chemistry was developed [75]. 
The washing and deprotection steps are performed together 
and the bags are combined for convenience. It is only the 
coupling step that is done individually in dedicated beaker 
reactors.  
Jofre et al. synthesized a library of peptide analogues 
between 16 and 20 amino acids in length derived from 
the  infectious pancreatic necrosis virus (IPNV) viral protein 
VP2 [76]. The original p20 peptide and all the variants 
showed activity against a variety of Gram-negative bacteria 
(V.ordalii, V. alginolitycus, V.anguillarum, A hydrophila, 
E.coli) and Gram positive bacteria (S.epidermidis, M.luteus) 
with MIC values ranging from 25-100µM. Furthermore the 
peptides showed no toxicity against eukaryotic cells 
(CHSE-214 or Chinok salmon embryo cells) at 10 times the 
concentration used for the antimicrobial assays. One of the 
peptides (GIM 444) showed a MIC of 25µM against E. coli, 
V. alginolitycus, V. ordalli and a MIC of 50µM against 
S.epidermidis.  
3.3. “Multi pin” method 
The method was originally designed by Geysen et al. for a 
96 well plate format based screen [72]. Similarly to the other 
methods mentioned above the “multi-pin” is a solid phase 
peptide synthesis where the peptides synthesized are 
attached to the tip of a polypropylene pin (4x44mm) 
functionalised by acrylic acid [47], which polymerizes on 
the surface of the pin so poly acrylic acid is formed. The 
pins are then mounted on a frame with the same dimensions 
as a 96 well microtiter plate. The wells of such a plate are 
then filled with activated amino acid solutions in which the 
multi-pin frame can be positioned so the polypropylene pins 
are placed in the activated monomer solution (see Figure 
3A). The scale of the technique can be very small (50 nmol), 
however such a scale is mainly used in binding experiments 
for epitope mapping of antibodies by screening the peptides 
afterwards using ELISA. The method was later developed 
to incorporate chemical linkers, which can be easily cleaved 
so the synthesized peptides can be screened in solution [77]. 
This also resulted in increased scale of the synthesis and 
multi-milligram quantities of the synthesized peptides, 
which also made their purification possible. For example 
Brogden et al. reported on the antimicrobial activity of 
propeptide fragments which were part of larger inactive 
proteins (zymogens) [78] with conserved homopolymeric 
regions of aspartic acid. These conserved negatively 
charged fragments can be part of hormones, enzymes and 
cationic proteins within the same animal species, however 
they can also be conserved between different animal species 
[78]. The study focused on the antimicrobial activities of 
propeptide fragments of ovine trypsinogen activated protein 
(TAP) and frog (Xenopus leavis) PYL activation peptide. 
The fragments were synthesized using the multi-pin method 
and were then cleaved, purified and screened for their 
antimicrobial activity. The results showed that the peptides 
were most active against Gram-negative bacteria (K. 
pneumonie, E. coli and P. heamolytica) with MICs ranging 
from 0.08-0.90mM,  but they were less active against Gram-
positive bacteria with  MIC’s ranging between 0.94 to 2.67 
mM (E. faecalis and S. aureus). Based on their results the 
authors were able to conclude that in addition to their charge 
neutralizing properties in larger proteins, propeptide 
fragments rich in negatively charged amino acids also have 
innate immune functions and might offer potential as new 
antimicrobials.  
Iwasaki et al modified a short antimicrobial peptide 
fragment of celeoptericin-A[79]. Celeoptericin-A is a 
protein isolated from the larvae of a beetle Allomyrina 
dichotoma after challenging with E. coli. Iwasaki et al. 
synthesized 53 overlapping sequences 20 amino acids in 
length with a frame shift of two residues by using the “multi-
pin” method. Two of the peptide fragments showed activity 
against E. coli, but not against S. aureus. These peptides 
were then used to create a second sub-library of peptides 
with increased hydrophobicity and net charge. From the 
sub-library one of the analogues showed greater activity 
than celeoprericin-A against E. coli (11µg/ml in comparison 
to 31.9µg/ml). Furthermore the peptide was also active 
against S. aureus, however less active than the full length 
celeoptericin-A.  
 
 
3.4. Libraries on cellulose support (SPOT synthesis) 
 
Peptide synthesis on a cellulose membrane is another way 
of creating peptide libraries. Defined peptides as well as 
combinatorial peptides can be synthesized. This method was 
developed by R. Frank in Germany more than 20 years 
ago[80]. Simple filter paper, like Whatman Chr1, 50 or 540 
can be used for the synthesis. In addition, specially 
optimized cellulose membranes for binding assays are 
commercially available [81]. The free hydroxyl groups of 
the cellulose are modified by natural or non-natural amino 
acids in order to have reactive amino groups available. Often 
a spacer is introduced to improve binding assays. 
Afterwards the peptide synthesis follows standard Fmoc-
Figure 4. Substitution analysis of the peptide Bac034 (VRLRIRVAVIRA-NH2), whereby the 12 mer peptide is 
substituted with all common proteinogenic amino acids barring cysteine, modified from Hilpert et al. 2006 [86]. The data 
can be plotted on a heat map where the darkest shaded cells represent the most active peptides, white is inactive. 
chemistry. A detailed protocol of the method was published 
previously [82]. For binding assays small spots (about 0.1μl 
spot volume) are sufficient for the experiments, whereas for 
other in vitro experiments where a higher yield is required 
large peptide spots (about 1.2 μl spot volume) are used. 
Typically 6000 - 8000 small spots or 600 - 800 large spots 
will fit on one cellulose sheet with a size of 18 x 29 cm.  
It was reported that using  glycine as a linker between the 
hydroxyl groups of the cellulose and the first amino acids of 
the desired peptides yields a peptide density of up to 
1.9  μmol/cm2 [83]. Optional, the peptides can be cleaved 
from the cellulose filter using different methods, ammonia 
gas being the most common [81]. In 2005 Hilpert et al. 
described the application of peptides synthesized by the spot 
synthesis method  in the field of antimicrobial peptides [84]. 
Large spots were synthesized using glycine as a linker. 
Peptides were cleaved from the cellulose by ammonia 
vapour and each spot was punched out individually and 
transferred into a 96 well plate. Peptides were dissolved in 
autoclaved distilled water [85] Bac2A (RLARIVVIRVAR), 
a linear variant of the bovine cathelicidin bactenecin 
(RLCRIVVIRVCR), was used to study the interaction with 
Pseudomonas aeruginosa in detail. In this study a 
bioluminescent P. aeruginosa was used to gain a fast and 
sensitive read out. A substitution analysis, comprising of 
228 systematic substitutions  of Bac2A, was synthesized. 
For each of the peptides a dilution series was performed and 
based on the concentration dependent activity against P. 
aeruginosa an IC50 for each peptide was calculated. This 
value was compared to the original activity of Bac2A and 
deeper and systematic insight of the interaction with the 
bacterium was achieved. Several single substituted peptides 
were synthesized on resin, purified and an MIC against 
different pathogenic bacteria and one yeast was performed 
to validate the data. An example of typical data obtained 
from substitution analysis is given in figure 4. The MIC of 
Bac2A against P. aeruginosa was determined as 50 μg/ml, 
using combinations of favourable substitutions within 
Bac2A the MIC improved to 2  μg/ml   for the peptides 
RRWRIVVIRVRR-NH2 and RRWRIVVIRVRR-
NH2.  Similar  investigations were performed on Bac034 
(VRLRIRVAVIRA-NH2), where a substitution analysis 
resulted in a deeper understanding of the interaction with P. 
aeruginosa and also in the identification of two novel 
peptides with improved antimicrobial activity 
VRLRIRVRVIRK-NH2 and KRWRIRVRVIRK-NH2 both 
showing an MIC value of 3 μg/ml  against P. aeruginosa 
compared to 25 μg/ml  of the Bac034 [86].These two 
examples show that this method can be successfully used to 
systematically optimize antimicrobial peptides. 
In the same publication the authors show that short 
antimicrobial peptides present a surprising feature [86]. In 
total, 49 scrambled variants of Bac2A (all different 
sequences but same amino acids) were synthesized and 
tested against P. aeruginosa. Within the 49 scrambled 
peptides some had antimicrobial activity superior or similar 
to Bac2A but also some were weaker or inactive. This 
experiment indicated the complexity of requirements for 
short active peptides. In addition, to add more complexity, 
the paper shows that a substitution within a 12 mer peptide 
will influence the effect of other substitutions at distant 
positions, here described by in initial substitution at position 
3 effecting the activity of a second substitution site at 
distance of 8 amino acids [86].  
A different approach to discovering novel antimicrobial 
peptide sequences is to screen biased or unbiased peptide 
libraries of random peptides. A peptide library containing 
200 members of unbiased random peptides was synthesized 
and screened against P. aeruginosa [87]. Only peptides with 
weak (53%) or no activity (47%) were found. Based on the 
data  from earlier experiments [82],[86] a new biased 
random peptide library was designed, synthesized and 
screened against P. aeruginosa. Here the amino acid 
occurrence probability within a random peptide creation 
was biased towards occurrence seen in former experiments 
with short active cationic antimicrobial peptides. The new 
peptide library comprising of 943 peptides showed 
3.2%  peptides with superior antimicrobial activity, 18.2% 
were active, 68.4% were weakly active and 10.2% were 
inactive [87]. A subsequent biased library was prepared and 
showed an improvement in activity, resulting in 
3.2%  superior antimicrobial peptides, 26.7% active, 61.1% 
weakly active and 8.9% inactive [87]. To further improve 
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the activity all the obtained data were used for a quantitative 
structure-relationship (QSAR) approach. Here a three 
dimensional structure was modelled for each peptide and 3-
D-sensitive properties of each peptides were obtained using 
‘inductive’ descriptors. Using an artificial neural network 
(ANN) QSAR was performed and novel peptides were 
predicted.  Highly active peptides were predicted with an 
accuracy of 94% [87]. The most active reported peptide 
KRWWKWWRR-NH2 showed a MIC of 0.7 μM against P. 
aeruginosa, in addition peptide KRWWKWIRW-NH2 
(MIC  of 0.8 μM)  was successfully tested in an infectious 
mouse model using a S. aureus infection [87]. Both peptides 
were also active against eight species of multidrug resistant 
bacteria [87]. Since the peptides showed such broad 
spectrum activity and as they could also kill multidrug 
resistant bacteria, a screen was performed against 
Mycobacterium tuberculosis. Tuberculosis still affects one 
third of the world’s population and multidrug resistance is 
rising. Ramón-García et al. report short cationic peptides 
that have broad spectrum activity and can also kill M. 
tuberculosis. The most active peptide was KWLKKWIK-
NH2 which showed a MIC of 1.1  μM against. M. 
tuberculosis [88].  
The previously described examples using the spot 
technology utilised cleaved peptides for the screen and 
optimisations. It is possible to screen for tethered peptides 
that are antimicrobial, as shown by Hilpert et al. 2009 [89]. 
These tethered peptides can then be used for protecting 
surfaces against infections, for example implants. This type 
of screen requires a different chemistry since the ester 
between the hydroxyl groups of the cellulose and the amino 
acid is not stable enough and could influence the results. 
Cellulose-amino-hydroxypropyl ether (CAPE) linker 
chemistry was used to screen for surface active 
antimicrobial peptides [89]. A series of surface active 
tethered peptides were identified and  subsequently 
developed further and grafted on polymer brushes [90]. 
These brushes were covalently bound to a titanium surface, 
a material frequently used for implants. Even tethered on the 
brushes peptides maintained excellent broad spectrum 
antimicrobial activity in vitro. Using a P. aeruginosa 
biofilm model, it was shown that these new surfaces had  an 
extremely effective protection against biofilm formation 
[90].  Titanium wires carrying these new type of peptide 
coupled polymer brushes  were used in a rat infection model 
and it was shown that the novel coating could protect the 
implants from infection  [90].  
Interestingly, experience gained using the aforementioned 
peptide libraries was used to design two new small libraries 
of peptides. K. Hilpert designed peptide libraries HH1 to 
HH18 and subsequently to further improve the library he 
designed  IDR-1001 to IDR-1048. Several investigations 
were carried out on these libraries. For example HH2, IDR-
1002 and IDR-1018 were shown to be potent innate defence 
regulators and could protect mice against M. 
tuberculosis  infections [91],[92]. Recently, it was reported 
that IDR-1018 has an anti-biofilm effect on several bacteria 
[93]  
 
3.5. Data analysis of peptides on cellulose spots 
 
The computer-based analysis of a given library can be 
summarized by an iterative process as shown in Figure 5. It 
starts with a first library version with peptide sequences and 
corresponding measurements for each of these peptides; see 
surveys in [94]–[96]. Typical measurements are binary 
classifications such as antimicrobial/non-antimicrobial, 
MIC values of peptides or dilution series of antimicrobial 
activity indicators such as luminescence values in luciferase 
assays. Various kinds of toxicity measurements can be 
added to rate not only the activity, but the therapeutic 
potential of peptides [97]. 
To analyse peptides, different descriptors are computed 
from the peptide sequences.  Such descriptors are amino 
acid composition, aggregated descriptors of amino acids 
(e.g., hydrophobicity and isoelectric point) or descriptors for 
physico-chemical properties of complete sequences (e.g., 
alpha-helix propensity [98],[99]. These descriptors are 
aggregated by Bayes classifiers [100], Neuro-Fuzzy models 
[99], Artificial Neural Networks [87],[98],[101] or Support 
Vector Machines [98],[101] to predict activity or toxicity for 
unknown peptide sequences. More powerful models can be 
designed if activity measurements against various microbes 
and toxicity values are available. Such models can be used 
to predict and select peptides that act only against specific 
microbes or to avoid toxic effects against human cells. It 
should be noted that all models are only reliable for peptides 
that are similar to peptides used for model design.  
Another analysis output is the result visualization using few 
powerful descriptors followed by the manual or the 
automatic generation of design rules for better peptides 
[101],[102]. Such rules should be understandable and based 
on intuitively interpretable descriptors, as e.g. amino acid 
compositions, promising motifs or established descriptors 
such as charge and hydrophobicity.   
The in silico synthesis of promising peptides by these design 
rules enriches peptides with desired properties to be 
synthesised in vitro as a first candidate set. By applying the 
previously generated model to predict activities or toxicities, 
a set of most promising peptide candidates can be selected 
for the next iteration in the library optimization 
process.  Such library optimizations were successfully 
applied for the increased activity of random and semi-
random libraries against P. aeruginosa  [87], M. 
tuberculosis [88]. 
3.6. Peptides libraries on glass slides  
Using standard peptide microarray technology tens of 
thousands of randomly designed peptides can be printed 
onto glass slides and then screened in situ against different 
species of bacteria[103]. In the work of Diehnelt et al. 
bacteria were labelled with two fluorescent dyes prior to the 
peptide screen, this allowed for the recognition of 3 different 
peptide classes, peptides that had no effect on the bacteria, 
those able to lyse bacteria and those able to bind but not lyse 
bacteria. Validation studies found that over 50% of the 
peptides that were able to lyse the bacteria in the initial 
screen were able to inhibit bacterial growth in standard 
bacterial growth inhibition assays. Diehnelt et al. used these 
results to create a hybrid peptide formed by conjugating a 
peptide which showed selective binding to S. aureus, and a 
peptide with antimicrobial activity towards S. aureus, this 
conjugation was found to increase the activity of the 
peptides and decrease their toxicity [103].  
 
4. Biological synthesized peptide libraries  
4.1. Peptide display  
Peptide display is a method where large libraries of DNA 
encoded peptides are screened to identify peptides with 
desirable properties. The peptides are maintained in 
association with the genes encoding them which allows for 
the amino acid sequence of the “hits” to be determined by 
gene sequencing technology.  Multiple rounds of selection 
during the screening procedure leads to increasingly optimal 
peptides being isolated, a process analogous to selection of 
optimal mutants in nature[104]. Because these techniques 
often rely upon biological processes the chemical diversity 
is generally limited to the 20 naturally occurring amino 
acids [105]. Several methods of peptide display have been 
developed for various biological applications but phage 
display is by far the most prevalent [106]. 
 
 
Figure 6. Different biological screening techniques that can 
be used in the identification of antimicrobial peptides (not 
to scale) A. Phage particles contain the candidate peptide 
attached as a fusion protein on the outer surface of the 
phage. B. ‘mRNA display’ where candidate peptides are 
linked to the coding mRNA by a puromycin linker. C. 
Transformed E.coli with ‘leaky’ membranes express 
candidate peptides. D. ‘Ribosome display’ the peptides are 
displayed in a combination with the ribosome and the 
mRNA still attached.    
 
4.2. Phage display  
Saturation mutagenesis using solid phase synthesis is the 
method of choice for synthesising  oligomeric DNA for 
library construction [107]. To introduce variability to the 
oligonucleotides equimolar concentrations of all four 
activated nucleotides can be used in the successive coupling 
steps. However to reduce the formation of stop codons that 
would result in truncated peptide or uninfective virions 
[107] each codon can be replaced with a NNK triplet, where 
“N” can be A, T, G or C and “K” can be G or T. The 
advantage of using the NNK codon is that it only encodes 
one stop codon as opposed to the three permeations that 
would occur if NNN were used [104]. Furthermore it 
reduces the standard genetic code from 64 to 32 codons 
which reduces bias for particular amino acids, yet still 
encodes each of the standard 20 amino acids [104]. Other 
methods that can be used for generating mutated 
oligonucleotides include PCR based approaches and in vitro 
chemical mutagenesis, a thorough explanation of these 
strategies can be found in [108]. Following construction of 
the mutated oligonucleotide library, the foreign DNA is 
ligated to a phage gene encoding either major or minor coat 
proteins and the vector transformed into the phage by 
electroporation [107]. 
The combinatorial peptide libraries are thus expressed as 
fusion proteins attached to the surface coat of a 
bacteriophage. These libraries can consist of a complexity 
Figure 5. Optimization strategy for peptide libraries 
(modified from [134]) 
that allows for every possible sequence of a 7 mer peptide 
to be displayed[109]. 
Identification of best peptide candidates revolves around the 
process of biopanning in which the phage (containing fused 
peptide on the surface of their protein coat) are presented to 
the bacteria, allowed time to bind and then washed several 
times with buffer to remove unbound phage. Only phage 
displaying peptides that are able to bind to the target cells 
remain, these bound phage are then eluted and amplified by 
infection in suitable host bacteria. The amplification in the 
infected host can result in  replication of 1000 viral particles 
per hour and due to the non lytic life cycle of filamentous 
phage the host cells are able to proliferate [110]. Repeated 
rounds of biopanning are conducted with increasing 
stringency. After several rounds the proportion of bound 
phage greatly increases[107] and these can then be 
amplified for genomic analysis to identify the peptide 
sequence. 
There are some drawbacks of phage display in the search for 
antimicrobial peptides for example the use of fusion as 
opposed to monomeric peptides, the fact that phage display 
has currently been restricted to gene encoded amino acids 
and that the screen is only able to identify peptides with high 
binding affinity as opposed to antimicrobial activity. 
However despite these limitations the use of vast peptide 
libraries is appealing and has led to some promising results 
for the identification of very selective peptides. 
Using the method of phage display a library of 12 mer 
peptides was screened for their ability to bind the membrane 
of E. coli. In order to identify narrow spectrum AMP’s a 
subtractive screen was first carried out against S. aureus, 
whereby peptides that showed affinity for this organism 
were removed. Following this, six rounds of biopanning 
against E .coli were carried out with the genes of the final 
bound peptides sequenced. One of these peptides was 
subsequently synthesised and MIC’s  determined against a 
range of organisms. Despite the fact that the phage display 
method does not screen for peptides that are necessarily 
antimicrobial and instead only identifies those that bind to 
the bacterial membrane, the peptide discovered showed a 
very reasonable MIC of 8 µg/ml. Furthermore, due to the 
initial subtractive screen the peptide showed no activity 
towards S. aureus, and also no activity towards 
Staphylococcus epidermidis, Bacillus cereus or Klebsiella 
pneumonia. The only other tested bacteria which the peptide 
showed activity towards was Pseudomonas aeruginosa. The 
selectivity of the peptide was also demonstrated by the fact 
that it showed no haemolytic activity when tested at a 
concentration of 500µg/ml [33] . 
A 15-mer phage peptide library was screened against 
Campylobacter jejuni, an important zoonotic pathogen that 
is commensal in broilers but causes acute enteritis in 
humans [111]. Prior to the affinity screen the library was 
subtracted twice against another Campylobacter strain to 
reduce the amount of peptides with low affinity binding and 
a high propagation rate [107]. Following the first affinity 
screen the remaining library was split into two and different 
washing buffers were subsequently used for selecting the 
phage, one of which contained a detergent (Tween-20). 
Following three rounds of biopanning the remaining bound 
peptides were identified revealing a range of different 
sequences. It was hypothesised that this wide sequence 
variability was due to the double subtractive step that led to 
the peptides binding to a range of different epitopes. 
Furthermore, the group of phage that were washed using the 
buffer containing Tween displayed different physical 
characteristics to those isolated in the absence of detergent, 
confirming that the choice of washing buffer is an important 
parameter affecting the final result. Antimicrobial assays 
carried out on the peptides identified in the screen showed 
them to be far less potent when separated from the phage. 
The antimicrobial activity was however maintained when 
the peptides were tested still attached to the phage in its 
denatured form. This exemplifies one of the drawbacks of 
the phage display method, as the peptides may behave 
differently when removed from the phage coat. Although it 
has been suggested that the phage itself could be used as a 
delivery vehicle [112].  In a separate study three rounds of 
biopanning against a 10 mer phage library was carried out 
against E. coli and several peptides were identified with 
moderate activity in their monomeric form (12% survival at 
125ug/ml). The level of activity however was significantly 
improved by a single amino acid substitution and 
synthesising the peptides in dendrimeric tetrabranched form 
[113]. 
As phage display is an effective method for finding peptides 
with high affinity binding to target bacteria it has also been 
used to identify peptide-phage-antibiotic complexes that can 
selectively deliver antibiotics to pathogenic cells[114]. This 
approach may mean drugs previously shelved due to lack of 
selectivity or high toxicity may yet have therapeutic 
potential. 
4.3. Peptide expressions in transformed E. coli 
Screening of peptides may become more efficient if non-
random libraries are utilised. Guralp et al [115] explored the 
use of a non-random, in silico designed library of peptides 
based around substituting the C-terminal region of the 
bacteriocin Pln-423 with different classes of amino acids. 
The procedure maintained the biological synthesis strategy 
as opposed to SPPS peptide synthesis as it allows for the 
generation of larger libraries. Peptides designed in silico 
were reverse translated into oligonucleotides which were 
synthesised onto glass slides using phosphoramidite 
chemistry and maskless photolithography.  
Oligonucleotides were then amplified by emulsion PCR and 
expressed in the periplasmic space of E. coli with leaky 
outer membranes. The transformed bacteria were then 
overlaid with the target strain and zones of inhibition were 
used to identify peptides with antimicrobial activity. 
Tominaga et al [116] used NNK oligonucleotides to create 
a library in which all the 44 amino acid positions of the 
bacteriocin pediocin PA-1 were substituted with different 
amino acids. The aim of the research was to identify the 
functional importance of each residue within the peptide. 
The DNA library was transformed into leaky E. coli cells 
and antimicrobial activity towards P. pentosaceus was 
determined by overlaying the clones with target 
bacteria.  The study identified eight essential residues which 
if replaced resulted in a loss of activity, and 7 variable 
residues which could be replaced and antimicrobial activity 
maintained. Multiple sequence alignment with other 
pediocin-like bacteriocins showed that 7 of the 8 essential 
residues were conserved among this class of peptides. 
There is one major advantage this method has over phage 
display and that is that it’s directly screening for peptides 
with antimicrobial activity, as opposed to merely identifying 
peptides with high binding affinity.  However, the reliance 
of the method on peptide diffusion to create zones of 
inhibition has limitation as peptides that do not diffuse 
effectively may produce smaller zones even if they are more 
antimicrobial. Furthermore there is a risk of false positives 
occurring due to clone to clone variation in peptide 
expression. 
4.4 Ribosome display  
In the aforementioned techniques a microbial host is 
required to express or amplify the peptide library. In the 
search for antimicrobial peptides this step is troublesome as 
there is the risk that the most potent antimicrobial peptides 
will simply kill the host bacteria [117]. An approach that 
overcomes this problem is the use of a cell free display 
system, such as the ribosome display methodology utilised 
by Xie et al [117]. In ribosome display a random DNA 
library is generated and its transcription and translation both 
take place in vitro. To form a stable peptide-ribosome-
mRNA complex (PRM), the mRNA contains a terminator 
sequence that forms a hairpin structure upon completion of 
translational elongation, the complex is further stabilised by 
reducing the temperature or introduction of 
chloramphenicol  [118]. Xie et al. screened a peptide library 
against bacterial and mammalian model membranes 
immobilised on magnetic beads. The membranes with 
attached PRM complexes could then be recovered with 
magnets and the mRNA from the complexes bound to the 
membrane eluted, purified and amplified by PCR for the 
next round of screening. Following 5 rounds of screening 50 
clones were sequenced and data analysis revealed several 
motifs were frequently occurring in these sequences with the 
most common being ALR and RVG, this suggests these 
motifs may facilitate membrane interactions. 
4.5. mRNA display  
Another cell free peptide display technique that has been 
used in the search for novel antimicrobials is mRNA 
display. This technology involves the use of a DNA library 
transcribed into mRNA followed by ligation with a 3’ 
puromycin moiety. Puromycin is a translational inhibitor 
antibiotic that forms a covalent bond with the peptide upon 
entering the A site of the ribosome and concurrently causes 
the peptide-mRNA fusion to be released. This complex is 
purified and followed by reverse translation of the mRNA, 
adding the cDNA construct to the complex for identification 
later [123]. 
As with other peptide display methods several selection 
rounds are undertaken against an immobilised target where 
the best hits are eluted and amplified at the end of each 
round. The best candidates after several selection rounds are 
sequenced for analysis. The complexity of mRNA libraries 
can be up to 1013 peptides [124] making it the most vast 
library discussed here. Furthermore the mRNA display 
complex can withstand harsher chemical treatments than 
ribosome display, a feature that can be useful during 
stringent selection steps [123]. As all steps of mRNA 
display are carried out in vitro they are more amenable to 
chemical modifications than methods requiring biological 
expression. To expand the chemical diversity of the peptide 
library Li et al [105]conjugated a penicillin moiety to 1012 
unique peptide sequences. These were then screened against 
PBP2a, the penicillin binding protein surrogate for PBP2 
found in methicillin resistant Staphylococcus aureus. PBP’s 
facilitate cell wall cross linking but in the presence of β-
lactam antibiotics the PBP gets acetylated inhibiting its 
function. Microbial resistance to β-lactams is conferred by 
both the slow rate of acetylation of PBP2a and its lack of 
high affinity for the β-lactam [125], thus finding ways of 
improving the affinity of β-lactams to PBP2a could be of 
great value. After 9 cycles of enrichment and amplification 
Li et al successfully used the library to isolate peptide-
penicillin conjugates that were 100 fold more active than the 
individual parent peptide.  
 
 
  
 
Sequence Array used 
Approximate 
number of 
peptides 
screened 
MIC [calculated µM] 
(target organism) 
Reference 
RLLFRKIRRLKR Phage display 1,000,000,000 8 µg/ml [5µM] (E.coli) [33] 
QEKIRVRLSA-CONH2 Phage display 1,200,000,000 
125µg/ml (12.5% 
survival)(E.coli) 
[113] 
VRKTTSHPPSYALLH Phage display 2,000,000,000 1.5µm (C.jejuni) [112] 
KYYGNGVTCGKHSCSVNWGQAFSCSVSRLANFGEGKC 
In silico design and microbial 
expression 
12000 0.037 µM (L. innocua) [115] 
RWRRHKHFKRPHRKHKRGSC Peptide microarray 10,000 28 µM (S. aureus) [103] 
WKWLKKWIK - CONH2 SPOT synthesis 282 1.1 µM (M. tuberculosis) [88] 
VRLRIRVRVIRK - CONH2 SPOT synthesis 228 
3 µg/ml [2µM] (P. 
aeruginosa) 
[86] 
KRWWKWWRR-CONH2 
In silico prediction and SPOT 
synthesis 
100,000 screened 
in silico, 200 
tested on using 
SPOT synthesis 
0.7 µM (P.aeruginosa) [91] 
Ac-RRWCKR-CONH2 Split and mix 160,000 
67-130µg/ml [70 - 
140µM] (C.albicans) 
[50] 
WGWRDIVRAIRKVAAPVLST Tea bag 20 
25µM (E.coli, 
V.alginolitycus, V. 
ordalli) 
[76] 
VGATWSKVIRGPGKSKPNWS Multi-pin 53 
11µg/ml [5µM] (E.coli), 
10.6µg/ml [5µM]  
(S.aureus) 
[79] 
RRWVRRVRRWVRRVVRVVRRWVRR Small peptide library 12 
0.3µM (S aurues, 
P.aeruginosa) 
[119] 
KWKSFLKTFKSAKKTLLHTALKAISS Small peptide library 7 
2 µg/ml [1µM] (P. 
aeruginosa) 
[120] 
KWKSFIKKLTKKFLHSAKKF Small peptide library 23 
0.5 to 8 µg/ml [0.2-3µM] 
Broad Spectrum 
(ESKAPE) 
[121] 
RRRWWWF-CONH2 Small peptide library 16 
4-8µg/ml (3.3-6.7µM) 
(Streptococcus mutans) 
[122] 
Table 2. A selection of antimicrobial peptides discovered using peptide libraries.  
  
 
 
5. Small peptide libraries  
For the purpose of this review small peptide libraries will 
consist of no more than 50 peptides. The small peptide 
library approach will almost exclusively follow a rational 
design of peptides of interest rather than a random approach. 
One of the easiest and most established ways to generate 
small peptide libraries is to take an existing peptide and 
modify it, which is mainly done through substitution of 
amino acids into each position of the peptide (if short 
enough in length) or at a particular position within the 
peptide. 
Such a library was created by Tan et al, where six amino 
acids (Alanine, Glycine, Glutamine, Leucine, Lysine, and 
Serine) were all  individually substituted into the 16th 
position of the parent antimicrobial peptide known as V13K 
[120]. They found that the more hydrophobic the amino acid 
substitution the more antimicrobial the peptide; however at 
the same time these peptides also exhibited the highest 
toxicity towards red blood cells.  
Mishra et al designed a library, by taking the first 8 N-
terminal residues from a well-studied antimicrobial peptide 
Lactoferrin. L1 (APRKNVRW) served as a template to 
create a further 9 variants. Initial screening against E. coli 
reported L10 (WFRKQLKW) having an MIC of 1 µg/ml. 
L10 was further tested against 30 multidrug-resistant 
isolates of extended spectrum β-lactamase (ESBLs) 
producing bacteria, including P. aeruginosa, K. pneumoniae 
and Acinobacter species with the MICs reported to be in the 
range of 1-8 µg/ml, while also having an MIC of 6.25 µg/ml 
against C. albicans. In addition L10 showed no hemolytic 
activity, even at high concentrations of 800 µg/ml[126]. 
 
Potent antimicrobial peptides such as tritrpticin and 
indolicidin are found naturally enriched in Trp residues 
[127],[128]; hence one approach in the field of antimicrobial 
peptides has been to enhance or design peptides by 
enriching them with tryptophan residues. The rationale 
behind this is that tryptophan has shown strong inclination 
towards lipid bilayers[129]. In keeping with this rationale, 
Deslouches et al designed a small antimicrobial peptide 
library exclusively consisting of peptides of different 
lengths containing just tryptophan and arginine. This 
resulted in the creation of a library of WR peptides ranging 
from 6 to 18 amino acids in length, with the most active 
peptide in their library being WR12, which showed activity 
against a wide range of MDR and XDR pathogens, 
including A. baumannii, P. aeruginosa and MRSA with 
MICs ranging between 4 and 11 µg/ml. However it only 
showed weak activity against K. pneumonia with an MIC of 
27 µg/ml [130]. Furthermore Deslouches et al later 
tested  peptide WR12 against the ESKAPE pathogens, as 
well as 100 clinical isolates. WR12 was reported to be active 
against these pathogens at concentrations ≤ 10 µM [131]. 
Jin-Jiang et al designed a peptide CP-P 
(KWKSFIKKLTSKFLHLAKKF-NH2) by splicing the 
sequences of peptides CP26 
(KWKSFIKKLTSAAKKVVTTAKPLISS-NH2) and P18 
(KWKLFKKIPKFLHLAKKF-NH2). The reasoning behind 
using CP26 and P18 as a basis for their design was due to 
these 2 peptides reportedly having strong antimicrobial 
activity. Furthermore they made a serine substitution on the 
16th position of CP-P, which resulted in a 75% improvement 
in the MIC (3.125 µg/ml) against P. aeruginosa, as 
compared the parent CP-P (12.5 µg/ml). Other variants were 
produced from the S16 parent by performing substitutions 
of amino acids at different positions. It was found that one 
of the peptides from the library with a Lys substitution at 
position number 11 (K11), showed a very low MIC against 
P. aeruginosa (1.6 µg/ml), as well as high activity towards 
various other gram negative and positive bacteria (0.5 to 8 
µg/ml), hence exhibiting a broad spectrum activity. The 
peptide also demonstrated very low haemolytic activity 
[121]. 
Alanine scanning is another method to create libraries. This 
is prepared by individually replacing each amino acid in the 
peptide sequence with alanine. This enables identification of 
specific amino acid residues which are responsible for the 
activity of the peptide. Alanine is most commonly used due 
to it being the smallest chiral amino acid, however other 
amino acid scans can also be performed.  McClean et al. 
used a soybean derived peptide as a starting point and 
carried out an alanine scan. Interestingly the variant 
sequence (PGAAVFK) showed an improved activity, with   
MICs of 12 and 36 µM against S. aureus and C. albicans 
compared to the original peptide (PGTAVFK), which had 
MICs of 31 and 201 µM respectively [132]. 
Alvarez-Ordonez et al. shortened a peptide, changed the 
amino acids sequence, performed an alanine scan, and 
enriched the peptide with Trp and Phe residues to determine 
how each can influence the activity of a peptide. They used 
the peptide αs2-casein f(183–207), which is a fragment of a 
milk derived peptide, αs2-casein. They found that removing 
the last 5 amino acids from the C-terminal caused a decrease 
in activity against the test pathogens Listeria. 
monocytogenes and Cronobacter sakazakii. Furthermore a 
variant αs2-casein f(183–207) V19 which had arginine 
replaced in the 23rd position with  an alanine caused a large 
decrease in activity against the test bacteria, as did 
replacement of other positively charged amino acids, 
indicating the importance of arginine and positive charge in 
the activity of this peptide. On the other hand, replacement 
of proline at positions 14 and 20 increased the potency. In 
addition enrichment of the peptide with Trp and Phe 
residues resulted in increased potency towards L. 
monocytogenes, however displayed no such effect against 
C. sakazakii [133]. 
 
 
Conclusion 
Whilst the number of antimicrobials entering the market is 
stagnating the levels of antimicrobial resistance seen 
amongst pathogens is rising. This means the search for 
effective and novel antimicrobials is both urgent and 
imperative. Antimicrobial peptides have the potential to 
curtail the problem, however with so many possible 
variations of the molecules identifying optimised candidates 
is challenging.  
Peptides libraries offer a solution to this, and we have 
discussed several different approaches that can be utilised in 
both the creation and the screening of the library. These 
different strategies each have their advantages and 
disadvantages but generally speaking the choice is between 
large libraries that have moderate predictive power towards 
finding an optimised peptide and smaller libraries with a 
more robust predictive power.   
Peptide libraries have already been used to find many 
peptides that have promising therapeutic potential and 
through strategies such as substituting amino acids into 
different positions within the peptide, along with 
bioinformatical analysis of large libraries a greater 
understanding of antimicrobial peptides can be achieved.  
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